HPC lays out new offices and duties under recent laws: pharmaceutical oversight and state health planning

Health Policy Commission leadership used the Sept. 18 meeting to walk commissioners through statutory changes enacted earlier in the year that expand the agency's duties and create two new, dedicated offices.

Executive Director David Seltz summarized the legislation (Chapters 342 and 343 of the Acts of 2024) as adding a broad mandate on pharmacy oversight and a renewed state health‑planning responsibility. "This office of pharmaceutical policy and analysis — OPA — is a mandate from the legislature for the HPC to create a dedicated office and staff it to really be focused on analyzing and understanding what is going on in the pharmaceutical sector," Seltz said, explaining the office will analyze PBM and pharmacy spending data, coordinate with CHIA data collections and issue annual reports and policy recommendations.

Seltz said the new Office of Health Resource Planning will undertake a five‑year state health plan to map supply and distribution of services, identify misalignments, and recommend ways to better align facilities and services with community need. He described it as a large undertaking that will combine data analysis, convening, and partnership with sister agencies including the Center for Health Information and Analysis (CHIA), the Department of Public Health and the Division of Insurance.

The legislation also broadens the HPC's market oversight triggers — adding changes of ownership involving significant equity investors, sales or transfers of assets including real‑estate leasebacks, and conversions from nonprofit to for‑profit status — and authorizes longer post‑transaction reporting (up to five years) for monitoring impacts. The law additionally directed creation of a Primary Care Payment and Delivery Task Force co‑chaired by the HPC and the Executive Office of Health and Human Services; the commission's staff are providing technical and data support to that 25‑member task force.

Commissioners asked about data timelines for pharmacy reporting and about how the new state health plan will be used by regulators and state programs. Staff said CHIA is standing up required PBM data collections and that the first OPA annual report is targeted for 2026, but that the precise timing depends on data readiness and data‑quality work. For the health resource plan, staff said the product is meant to inform processes such as the Department of Public Health's determination‑of‑need reviews and to spot aggregate trends that single transactions might obscure.

Staff said they are staffing both offices and plan public rulemaking and data‑specification processes in the months ahead.